RiceBran Technologies (NDAQ:RIBT) Moves On Lake Street Initiation with $2.00 Target, Avexis (AVXS) Shorts Decreased By 8.74%

May 11, 2017 - By Marie Mckinney

It is up 36.76% since October 4, 2016 and is downtrending. It has underperformed by 48.35% the S&P500.

Avexis Incorporated (NASDAQ:AVXS) had a decrease of 8.74% in short interest. AVXS’s SI was 5.11M shares in May as released by FINRA. Its down 8.74% from 5.60M shares previously. With 660,100 avg volume, 8 days are for Avexis Incorporated (NASDAQ:AVXS)’s short sellers to cover AVXS’s short positions. The SI to Avexis Incorporated’s float is 31.99%. About 75,119 shares traded. AveXis Inc (NASDAQ:AVXS) has risen 83.08% since October 4, 2016 and is uptrending. It has outperformed by 71.49% the S&P500.

Among 4 analysts covering AveXis (NASDAQ:AVXS), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. AveXis had 5 analyst reports since May 13, 2016 according to SRatingsIntel. The rating was upgraded by Jefferies on Friday, August 12 to “Buy”. Jefferies maintained AveXis Inc (NASDAQ:AVXS) on Monday, September 19 with “Buy” rating. The stock has “Buy” rating by Bank of America on Friday, October 21. The company was initiated on Friday, July 15 by Wells Fargo. Goldman Sachs maintained the stock with “Buy” rating in Friday, May 13 report.

AveXis, Inc. is a clinical-stage gene therapy company. The company has market cap of $2.14 billion. The Firm operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. It currently has negative earnings. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analysts await RiceBran Technologies (NASDAQ:RIBT) to report earnings on May, 15.

RiceBran Technologies is a human food ingredient, functional food ingredient, packaged functional food and animal nutrition company. The company has market cap of $9.40 million. The Firm is focused on processing and marketing of nutrient dense products derived from raw rice, an underutilized by-product of the rice milling industry. It currently has negative earnings. The Firm has two operating divisions.